Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: GeneDx | Sema4 OpCo, Inc. | Sema4 OpCo, Inc | Sema4 OpCo Inc. | Sema4 OpCo Inc
Related tests:


GeneDx announces data demonstrating that whole exome and genome sequencing report fewer variants of uncertain significance (VUS) than multi-gene panel testing published in Genetics in Medicine (BioSpace)
"GeneDx...announced that Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG) has published a peer-reviewed research analysis resulting from a multi-lab collaboration involving GeneDx. The study, 'The landscape of reported VUS in multi-gene panel and genomic testing: Time for a change,' evaluated the rate of inconclusive genetic variants, or variants of uncertain significance (VUS), reported with multi-gene panels versus exome and genome sequencing."
Clinical data
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels (Sema4 Press Release)
"Sema4...has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using exome or genome sequencing results in a significantly lower rate of variants of uncertain significance (VUS) compared to panel-based testing, underscoring the importance of genomic sequencing for improving diagnoses and health outcomes. It is one of more than a dozen studies Sema4|GeneDX is either presenting, or has participated in, being showcased at the American Society of Human Genetics (ASHG) Annual Meeting."
Licensing / partnership
Avera Health and Sema4 announce data-driven study to advance cancer treatment across the Avera service area (Sema4 Press Release)
"Avera Health...and Sema4...announced the Avera/Sema4 Oncology and Analytics Protocol (ASAP) study, a five-year commitment to population health for precision oncology care...Avera and Sema4 will leverage Sema4 Signal® Whole Exome/Transcriptome Sequencing (WES/WTS), which captures data from approximately 18,500 genes, to enable comprehensive molecular profiling of a patient’s tumor tissue. The ASAP study will also include Sema4 Signal® Hereditary Cancer, one of the most comprehensive hereditary cancer testing panels available, to inform better care decisions for individuals with and without a concurrent cancer diagnosis."
New trial
Sema4 Signal®
Sema4 announces nationwide expansion of disparity study to deliver precision oncology care to underserved communities (Sema4 Press Release)
"Sema4...announced the nationwide expansion of its disparities in cancer care study. The study, launched in 2021, enables access to comprehensive genetic and genomic testing for advanced cancer patients in underserved communities...The REsearch to advance PREciSion medicine and health Equity in oNcology Treatment (REPRESENT) study, which is already enrolling patients at five locations across two sites, will run nationally in collaboration with community oncologists caring for patients with advanced cancer in diverse and traditionally understudied and underserved populations."
Trial status
Sema4 Signal®